ArticleHuman vaccines & immunotherapeutics2023

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.

Derek Lytle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.